OBJECTIVE: To examine if the prophylactic use of vaginal Utrogestan from the first-trimester of pregnancy in women with twin pregnancy can reduce the incidence of spontaneous delivery before 34 weeks., METHODS: Phase III two-arm double-blinded randomised controlled trial to examine the effect of prophylactic pravastatin from 35-37 weeks' gestation in women at increased risk for term-PE on the incidence and severity of the disease., PRIMARY OUTCOME: delivery with preeclampsia. , SECUNDARY OUTCOME: determine the effect of pravastatin., On adverse outcome of pregnancy at any gestation and at = 37 week´s gestationOn the incidence of stillbirth or neonatal death. On neonatal morbidity. , On neonatal therapy. , On the incidence of low birth weight below the 3rd, 5th and 10th centile. , On sFLT and PLGF value 1 and 3 weeks after the onset of treatment. , Pravastatin safety assessment during pregnancy.
preeclampsia
embarazo
pravastatina
Acción Estratégica en Salud (AES)
01/01/2018 - 31/12/2020
DELGADO MARIN, JUAN LUIS
FUNDACION PARA LA FORMACION E INVESTIGACION SANITARIAS DE LA REGION DE MURCIA (FFIS)
INSTITUTO MURCIANO DE INVESTIGACION BIOSANITARIA (IMIB)
Región de Murcia
Murcia
123,420 €